---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Definition and etiology"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Definition and etiology. Topics: Guideline definition: autosomal recessive neurovisceral lysosomal disorder, Genetic basis and diagnostic definition, Proportion of cases attributed to NPC1 and NPC2, Autosomal recessive inheritance and recurrence risk, and 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Guideline definition: autosomal recessive neurovisceral lysosomal disorder

> “Statement #1: NPC is a progressive and life‐limiting autosomal recessive, neurovisceral lysosomal disorder caused by pathological variants in either NPC1 or NPC2.”
> “Variants in these genes are associated with abnormal endosomal‐lysosomal trafficking, resulting in the accumulation of unesterified cholesterol and other lipids in the lysosomes.”
> “Disease onset varies, ranging from antenatally to throughout the lifespan.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.1-2"></a>

### Genetic basis and diagnostic definition

> “The diagnosis of NPC is established in a proband with suggestive findings and biallelic pathogenic variants in either NPC1 or NPC2 identified by molecular genetic testing.”
> “The terms Niemann-Pick disease type C1 (NPC1) and Niemann-Pick disease type C2 (NPC2) are now preferred because they correspond with the associated genes (NPC1 and NPC2).”
> “The term Niemann-Pick disease type D describes a genetic isolate from Nova Scotia that is biochemically and clinically indistinguishable from NPC and that also results from biallelic pathogenic variants in NPC1.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.1-3"></a>

### Proportion of cases attributed to NPC1 and NPC2

| Gene | Proportion of NPC attributed to pathogenic variants in gene |
| --- | --- |
| NPC1 | “95%” |
| NPC2 | “5%” |

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.1-4"></a>

### Autosomal recessive inheritance and recurrence risk

> “NPC is inherited in an autosomal recessive manner.”
> “If both parents are known to be heterozygous for an NPC-related pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants.”
> “The NPC phenotype usually runs true in families; that is, if the proband has early-onset disease, sibs who inherit biallelic pathogenic variants will have a similar clinical course.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.1-5"></a>

### Genetic etiology and clinical forms by age at onset

> “Niemann-Pick disease type C (NPC) is an autosomal recessive disorder caused by pathogenic variants in NPC1 (OMIM 257220, HGNC:7897) or NPC2 (OMIM 607625, HGNC:14537)”
> “The infantile-onset form of NPC is characterized by cholestatic liver disease, hepatosplenomegaly, and pulmonary infiltrates, whereas later presentations include progressive neurologic symptoms, including cognitive impairment, cerebellar ataxia, psychiatric manifestations, and seizures, in addition to visceral disease.”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

<a id="topic-2.2.1.1-6"></a>

### Definition of infantile-onset NPC: sponsor statement

> “Infantile-onset NPC (I-NPC) refers to NPC in infants and children who first experience neurological symptoms before six years of age.”
> “Niemann-Pick disease, type C (NPC) is a rare, autosomal-recessive, severe, heterogeneous, neurodegenerative disorder caused by pathogenic variants in the NPC1 (~95% of cases) or NPC2 genes, leading to impaired intracellular cholesterol trafficking resulting in progressive neurological decline and premature mortality.”

Source: [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)

<a id="topic-2.2.1.1-7"></a>

### Classification by age at onset of neurological manifestations

> “Nevertheless, NPC is best classified according to the age at onset of neurological manifestations, as this correlates with prognosis, as follows:”
> “Pre/perinatal (< 2 months)”
> “Early infantile (2 months–2 years)”
> “Late infantile (2–6 years)”
> “Juvenile (6–16 years)”
> “Adult (> 16 years)”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.1-8"></a>

### Alternative onset-category thresholds in a registry-based survival study

> “Miglustat‐treated and untreated patients overall and within sub‐groups according to age‐at‐neurological‐onset, that is, early infantile‐onset (<2 years), late infantile‐onset (2 to <6 years), juvenile‐onset (6 to <15 years), and adolescent/adult‐onset (≥15 years) were analysed and compared.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
